OBJECTIVES: Education in pharmacoeconomics is one of the primary goals of ISPOR. This study is aiming to explore the needs for pharmacoeconomic educations by national chapter among different pharmaceutical stakeholders. METHODS: Inquiry research was performed among the participants in 2 educational initiatives of the Bulgarian ISPOR chapter. In both seminars attended representatives of payers - Bulgarian government (MoH, NHIF), as well as from pharmaceutical business, non- governmental organizations and academia. On total 48 individuals left feedback from over 60 participants in both seminars. The questionnaires focused on the topics covered in the seminars, organizational matters and needs of new educational themes. Preferred themes were assessed and results are consolidated RESULTS: Both seminars target the same groups of individuals – institutions, academia, pharmaceutical business, and non-governmental organizations. The first seminar was focused mainly on the pricing and reimbursement of the pharmaceuticals with international lecturers, while the second one covered basic pharmacoeconomic methods with national lectures. The overall satisfaction score from both seminars was very high (25%) and excellent (55%). The most preferred topic was the pricing and reimbursement of pharmaceuticals by 53%, followed by different modeling techniques (47%). Participants wanted to know more about the way of regulatory usage of pharmacoeconomics in pricing and reimbursement (70%). Focus groups discussion (98%) and practical of pharmacoeconomic were also a matter of high preference (30%).   CONCLUSIONS: This study proves the necessity for education in the field of pharmacoeconomic, modeling, core models explanations and pharmaceuticals assessment. They also pointed out the place of national chapters as providers of education and independent organizers able to gather different stakeholders’ point of view in non-formal discussions. Having in mind that BG is in the beginning of the HTA process obviously willingness to be educated among the whole Pharma environment is definitely high.